NLS Pharmaceutics (NLS Pharmaceutics) Interest Expense : $-0.15 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. NLS Pharmaceutics's interest expense for the six months ended in Dec. 2023 was $ -0.15 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.15 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. NLS Pharmaceutics's Operating Income for the six months ended in Dec. 2023 was $ -4.26 Mil. NLS Pharmaceutics's Interest Expense for the six months ended in Dec. 2023 was $ -0.15 Mil. NLS Pharmaceutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NLS Pharmaceutics Interest Expense Historical Data

The historical data trend for NLS Pharmaceutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Interest Expense Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.82

-0.23

-0.07

-0.10

-0.15

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial								-	-0.01	-0.09	-	-0.15

NLS Pharmaceutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.15 Mil.

NLS Pharmaceutics (NAS:NLSP) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NLS Pharmaceutics's Interest Expense for the six months ended in Dec. 2023 was $-0.15 Mil. Its Operating Income for the six months ended in Dec. 2023 was $-4.26 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was $0.00 Mil.

NLS Pharmaceutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

NLS Pharmaceutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.